Aegis Capital Keeps Buy on Acorda (ACOR); GGF2 Progress In-Line, Q3 Should ... StreetInsider.com (subscription) The trial design included seven cohorts of six participants each, four of whom received GGF2 and two of whom received placebo at each dose. In the study, a single infusion of GGF2 in patients with heart failure was generally well-tolerated up to dose ... |
